American Bio Medica Receives Second Patent in the UK.Business Editors KINDERHOOK, N.Y.--(BUSINESS WIRE)--October 10, 2000 American Bio Medica medica (māˑ·dē·k Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ABMC ABMC American Battle Monuments Commission ABMC Alexian Brothers Medical Center (Illinois) ABMC Aviation Battle Management Concept ABMC Arrowbear Music Camp (California) ), which develops, manufactures and markets drugs of abuse diagnostic kits, sprays and support services support services Psychology Non-health care-related ancillary services–eg, transportation, financial aid, support groups, homemaker services, respite services, and other services , today announced that it has received a patent in the United Kingdom, which covers the test card and also the process for testing of a fluid sample for drugs. This subject patent is a division of the United Kingdom patent that the Company received in December 1999, which covered the combination of components of the Rapid Drug Screen(TM) on-site substance abuse test kit. ABMC feels that the combination of the two patents issued in the United Kingdom expands global protection of its intellectual property rights related to the Rapid Drug Screen drug test. ABMC Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Stan Cipkowski commented, "The additional UK patent further confirms that the features of our Rapid Drug Screen products, which provide us with an edge over our competitors in the drug testing industry, are unique. This will allow our market positioning in the UK to improve as we rid the United Kingdom of copycat products, most of which are produced in the United States by infringers of our United States patents. Some of those infringers are defendants in ABMC's federal patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. suit pending in California." The Rapid Drug Screen single-step tests for substances of abuse generate results in five minutes and are unrivaled for ease of use. The most secure and flexible total testing system on the market, ABMC's on-site tests simultaneously screen for the presence or absence of up to nine illicit drugs. American Bio Medica Corporation develops, manufactures and markets inexpensive, accurate on-site drugs-of-abuse diagnostic kits, sprays and support services worldwide. The company's global distributors target the workplace, physicians, corrections, clinical and educational markets. ABMC's Drug Detector(TM) identifies minute traces of illegal drugs on surfaces, while the company's Rapid Drug Screen tests individuals and is proven to correlate 100% with the standard laboratory screening test. Forward-looking statements in this release are made pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risk and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, intellectual property rights and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion